Previous 10 | Next 10 |
Inventiva S.A. (IVEVF) Q4 2020 Earnings Conference Call March 5, 2021 08:00 ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer and Co-Founder Pierre Broqua - Chief Scientific Officer and Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief...
The following slide deck was published by Inventiva S.A. in conjunction with this event. For further details see: Inventiva (IVEVF) Investor Presentation - Slideshow
Clinical-stage biopharmaceutical company Inventiva (IVA) announces the details of the Phase 3 trial evaluating its lead drug candidate lanifibranor in NASH following the end-of-Phase 2 meeting with the FDA.Non-alcoholic steatohepatitis ((NASH)), is a fatty liver disease due to obesity.As...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
The FDA has designated Fast Track status to Inventiva's (IVA) odiparcil for the treatment of MPS type VI (MPS VI), a rare and progressive genetic disorder.The Fast Track program facilitates the development and expedite the regulatory review and potential approval of drug candidates.Odiparcil ...
Gainers: [[ETH]] +11.8%. [[SOS]] +9.0%. [[DIS]] +5.3%. [[EXC]] +5.1%. [[IVA]] +4.2%.Losers: [[VYGR]] -13.9%. [[HX]] -9.2%. [[IH]] -3.5%. [[CVI]] -2.4%. [[ICLK]] -2.1%. For further details see: ETH, DIS, VYGR and CVI among after-hours movers
The FDA designates Inventiva's (IVA) lanifibranor, a Breakthrough Therapy for the treatment of non-alcoholic steatohepatitis ((NASH))The Breakthrough Therapy designation expedites the development and review of drug candidates, as well as provides for more intensive guidance from the FDA on de...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors head into next week with a few October surprises already in the books. Stimulus drama and further developments...
Following an active September, two IPOs are scheduled to raise $200 million in the week ahead. Several companies could join the IPO calendar early in the week, such as Spruce Biosciences, Shattuck Labs, and Kronos Bio. Live TV streaming platform fuboTV plans to raise $150 million ...
News, Short Squeeze, Breakout and More Instantly...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...